Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Financial ResultsItem 2.02 · 8-KLOW RiskNeutral

Intensity Therapeutics, Inc.

Filed: Mar 27, 2026CIK: 0001567264
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Intensity Therapeutics released its 2025 annual financial results on March 27, 2026, providing shareholders with performance metrics and operational updates that are critical for assessing the company's financial health and investment viability.

Key Takeaways

Company disclosed full-year 2025 financial results through a press release filed as Exhibit 99.1

Filing serves to inform shareholders about financial condition and operational performance throughout fiscal year 2025

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMar 27, 2026
Item2.02
CategoryFinancial Results
CIK0001567264
Accession #20260327
Risk LevelLOW
SentimentNeutral
Signalinformational
Topics
earnings

What This Means

The company is reporting financial results. Look for revenue trends, profitability changes, and forward guidance.
View Full Filing on SEC.govBrowse More Filings